Boozman ... invited ... to rally support for his bipartisan initiative that would increase access to prostate cancer screenings.
Advance bipartisan legislation to increase access to prostate cancer screenings.
Occurrences
Evidence
On March 20, 2026, Senator John Boozman advocated for his bipartisan PSA Screening for HIM Act during a Senate Health, Education, Labor, and Pensions (HELP) Committee hearing. The bill aims to require private health insurance plans to cover preventive prostate cancer screenings without cost-sharing for high-risk men.
On March 10, 2026, Senator Boozman received the 2026 Prostate Cancer Champion Award from ZERO Prostate Cancer for his leadership in advancing policies that enhance prostate cancer care and research, including his efforts on the PSA Screening for HIM Act.
The PSA Screening for HIM Act (S.297) was introduced by Senator Boozman on January 29, 2025, and referred to the Senate Committee on Health, Education, Labor, and Pensions. The bill seeks to mandate insurance coverage for prostate cancer screenings for high-risk men without cost-sharing.
Sponsor: Sen. Boozman, John [R-AR] (Introduced 01/29/2025). Latest Action: Senate - 01/29/2025 Read twice and referred to the Committee on Health, Education, Labor, and Pensions. Tracker: This bill has the status Introduced.
01/29/2025 | Read twice and referred to the Committee on Health, Education, Labor, and Pensions. Action By: Senate
The committee's Member Day page lists S. 297, PSA Screening for HIM Act, among the measures discussed at the hearing.
Boozman said the PSA Screening for Him Act is legislation 'we're proud to lead with Senator Booker' to expand insurance coverage for lifesaving screenings for men who are at high risk for prostate cancer.
Congress.gov shows S.297 (PSA Screening for HIM Act), sponsored by Sen. John Boozman, was introduced on January 29, 2025 and its Latest Action is recorded as 'Read twice and referred to the Committee on Health, Education, Labor, and Pensions' with bill status 'Introduced'. No subsequent committee report, floor action, passage, or enactment is listed.
Senator Boozman's official Senate press release (Mar 20, 2026) documents his active advocacy for the bipartisan PSA Screening for HIM Act at a Senate HELP Committee hearing, describing his urging of committee support and emphasizing the bill's requirement that private plans cover preventive prostate cancer screenings for high-risk men without cost-sharing.
Assessments
Boozman did take concrete same-term action on this promise: he sponsored the bipartisan PSA Screening for HIM Act, S.297, on January 29, 2025 and continued advocating for it at a Senate HELP Committee hearing in March 2026. That shows real effort to advance bipartisan legislation on prostate cancer screening. But as of June 21, 2026, Congress.gov still shows the bill only at the introduced-and-referred stage, with no committee report, floor passage, enactment, or demonstrated policy change increasing screening access. Because he materially advanced the proposal but did not deliver the underlying access expansion or major legislative progress, partial credit fits best.
Sen. Boozman sponsored and introduced S.297 (PSA Screening for HIM Act) on 01/29/2025 and actively promoted it at a Senate HELP Committee hearing in March 2026, showing clear legislative advancement and bipartisan sponsorship. Congress.gov records the bill as read and referred to committee with no subsequent committee report, floor action, passage, or enactment, so the promised expansion of access was not enacted—only advanced.
Boozman sponsored and actively advocated the bipartisan PSA Screening for HIM Act, including introduction in January 2025 and promotion at a March 2026 HELP Committee hearing, which satisfies meaningful advancement of relevant legislation. However, the record shows the bill remained introduced/referred to committee with no passage or enacted screening-access expansion, so the promised policy outcome was not fully delivered.
Senator Boozman introduced bipartisan legislation (the PSA Screening for HIM Act) and actively advocated for it in committee hearings. However, there is no evidence the bill was passed into law or that access to screenings was actually increased during the term. The record shows significant legislative effort but no delivered policy outcome yet.